Expanded access to mezigdomide for eligible patients
Treatments studied
This trial offers expanded access to mezigdomide for patients who have exhausted other treatment options. It may help those with certain cancers, though the exact details are not listed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a condition that mezigdomide is intended to treat.
- Your doctor must be willing to work with the study team to request access.
- You must not have any other treatment options that are likely to work.
- You must meet the specific medical criteria set by the expanded access program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, mezigdomide (a pill) and elranatamab (an injection), for people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find the best dose and see if the combination is safe and effective.
This trial tests a new drug called mezigdomide (CC-92480) for people with multiple myeloma who have already received the CAR T-cell therapy Abecma. The goal is to see if mezigdomide can help keep the cancer under control after Abecma.
This is a special program that lets people with serious blood conditions try an investigational drug called iberdomide when no other treatments are available. It's not a clinical trial—it's a way to request early access to a promising medicine.
This trial tests a combination of two drugs—teclistamab (an immunotherapy) and mezigdomide (a targeted pill)—for people with multiple myeloma that has come back or not responded to previous treatments. The goal is to see if this new combination can help when other options have stopped working.
This trial tests a combination of two drugs, mezigdomide (a pill) and talquetamab (an injection), for people with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to see if this combination can help control the disease.
This Phase 3 study compares two combination treatments for multiple myeloma that has come back or not gone away (relapsed or refractory). It aims to see whether mezigdomide, along with bortezomib and dexamethasone, works better than pomalidomide with those same medicines.